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Abstract
Background: Primary systemic vasculitis presenting in childhood is an uncommon but serious condition. As these
patients transfer to adult clinics for continuing care, defining long term outcomes with emphasis on disease and
treatment- related morbidity and mortality is important. The aim of this study is to describe the long- term clinical
course of paediatric patients with ANCA vasculitis.
Methods: The adult patients in our vasculitis clinics who had presented in childhood, with a follow up time of
greater than 10 years were included. We also reviewed the literature for articles describing the clinical outcome of
paediatric patients with ANCA vasculitis.
Results: We describe the clinical course of 8 adults who presented in childhood with ANCA vasculitis. 7 patients
had Wegener’s granulomatosis and 1 had microscopic polyangiitis. The median age at presentation was 11.5 years,
and follow up time ranged form 11 to 30 years. Induction therapy for all patients was steroids and/or
cyclophosphamide. Maintenance therapy was with azathioprine or mycophenolate mofetil. Biological agents were
used in 3 patients for relapsed disease in adulthood only.
Seven patients achieved complete remission. All patients experienced disease relapse, with a median of 4 episodes.
Kidney function was generally well preserved, with median eGFR 76 ml/min. Only one patient developed end-
stage renal failure and one patient died after 25 years of disease. Treatment-related morbidity rates were high; 7
suffered from infections, 4 were infertile, 2 had skeletal complications, and 1 developed malignancy.
Conclusion: Close long- term follow up of paediatric patients with ANCA vasculitis is imperative, as this patient
cohort is likely to live long enough to develop significant treatment and disease- related morbidities. Prospective
cohort studies with novel therapies including paediatric patients are crucial to help us determine the best
approach to managing this complex group of patients. In addition, although not yet observed in our series, late
cardiovascular morbidity remains a major longer-term potential concern for adult survivors of paediatric vasculitis.
Background
Primary systemic vasculitides, with the exception of
Henoch Schönlein purpura (HSP) and Kawasaki disease
(KD), are diseases that predominantly affect people later
in adulthood, typically in their sixth and seventh decades
[1]. Vasculitides such as Wegener’s granulomatosis
(WG) and polyarteritis nodosa (PAN) have different
aetiological, clinical, and prognostic features in children
[2,3]. While there are numerous studies describing the
long- term outcome in adults with ANCA vasculitis, to
date the vast majority of published studies on paediatric
patients with ANCA vasculitis have a limited follow up,
at which stage they may be transferred to the adult vas-
culitis service. Furthermore, there are few data on the
progression of paediatric ANCA vasculitis patients into
adulthood, which is primarily due to the rare occurrence
of these disease entities in childhood.
The commonest childhood vasculitides are HSP and
KD, the estimated incidence of which is 20 per 100 000
children and 8 per 100, 000 children under 5 years in
the UK population respectively [4,5]. By contrast the
incidence of paediatric WG and microscopic polyangiitis
(MPA) is significantly less or unknown. The estimated
incidence of childhood WG is less than 1 per 2 million
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mined in paediatric patients.
In this retrospective study, we reviewed the clinical
features of 8 children diagnosed with ANCA vasculitis
and the progression of their disease into adulthood.
Diagnoses were made based on clinical criteria, labora-
tory testing, and histology, as well as the EULAR/PReS
proposed consensus criteria for the classification of
childhood vasculitides [7].
The objective of the study was to determine the pro-
gression of the clinical features of childhood ANCA vas-
culitis into adulthood, and to determine the long- term
disease and treatment- related morbidities. Particular
emphasis was placed on establishing long- term compli-
cations, and the total burden of immunosuppression, in
relation to relapse rate and treatment- related morbidity.
In addition, a literature review was performed to bet-
ter determine the common clinical features and out-
come of these patients.
Methods
We performed a retrospective study of patients attend-
ing the adult vasculitis clinic at Hammersmith Hospital,
London and the University Hospital of Birmingham.
From the vasculitis databases, patients with ANCA vas-
culitis who presented before the age of 16 years were
identified. Only those who had been followed for more
than 10 years were included in our cohort.
Patient demographics and clinical course (age of pre-
sentation, clinical features on initial and subsequent pre-
sentations, immunosuppression, complications of
treatment and the underlying disease and relapse rate)
were determined from the case notes. Results of bio-
chemical, histological, and radiological investigations
were determined from the hospital patient records
database.
ANCA associated vasculitis was diagnosed according
to the EULAR/PReS proposed consensus criteria for the
classification of childhood vasculitides [7,8], summarised
below. In brief, a diagnosis of Wegener’s granulomatosis
(WG, now termed granulomatosis with polyangiitis)
required three of the following features; abnormal urina-
lysis, granulomatous inflammation on biopsy, nasal sinus
inflammation, subglottic, tracheal, or endobronchial ste-
nosis, an abnormal chest X-ray or CT and PR3-ANCA
or C-ANCA staining by indirect immunofluorescence. A
diagnosis of microscopic polyangiitis (MPA) was based
on a clinical constellation of necrotising pauci-immune
vasculitis affecting predominantly small vessels asso-
ciated with a high titre of MPO-ANCA or positive p-
ANCA staining, necrotising glomerulonephritis, or pul-
monary capillaritis in the absence of granulomatous
lesions of the respiratory tract.
The primary outcome studied was mortality. Second-
ary outcomes included the occurrence of treatment and
disease related complications, time to first relapse, and
number of relapses. All data are presented as medians
and ranges.
We reviewed all articles listed on Pubmed describing
the outcomes of paediatric vasculitis. This included both
prospective and retrospective studies, observational data,
case series, and case reports. Search terms included
‘paediatric, vasculitis, Wegener’s granulomatosis, micro-
scopic polyangiitis, ANCA, churg strauss, and
autoimmune’.
Results
Demographics
There have been a total of 48 paediatric patients diag-
nosed with ANCA vasculitis between the years of 1996
and 2010 at the Great Ormond Street Hospital. 5 of
these patients were under adult follow up at the Ham-
mersmith Hospital, London, with more than 10 years
from initial diagnosis (Table 1). The University Hospital
of Birmingham has a total of 220 patients with vasculitis
under active follow up. 7 of these patients presented
with vasculitis in childhood, 3 of whom had ANCA
associated vasculitis and were under adult follow up
with at least 10 years from initial diagnosis.
Of the 8 patients, 2 were male and 6 were female. 6
patients were Caucasian, and 2 were African. Wegener’s
granulomatosis was the commonest diagnosis, present
in 7 patients, while only 1 had MPA. The median age at
presentation was 11.5 years (range 9 months to 15
years). Follow up time ranged form 11 to 30 years, with
a median and mean of 19 years. Four patients were
cANCA positive (all 4 with WG), 2 were pANCA posi-
tive (one with WG and one with MPA), and 2 were
ANCA negative (both with WG).
Clinical features
Arthralgia was the commonest clinical feature on initial
presentation, present in 6 patients (Table 2). In addition,
5 patients presented with pulmonary disease with fea-
tures of either intra- alveolar haemorrhage or cavitating
pulmonary nodules.
5 patients experienced renal disease with microscopic
haematuria and 4 had acute renal failure on presenta-
tion. 1 patient was dialysis dependent (Patient 7), while
renal function in the remaining patients was within the
normal range. Four patients had ear nose and throat
(ENT) symptoms of sinusitis, epistaxis, hearing loss or
nasal disease at presentation. All of these patients had a
clinical diagnosis of WG, while 1 of the patients also
had tracheal stenosis and poor vocal cord movement
(Patient 5).
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patients at presentation (with WG), manifesting as iritis
and scleritis. Gastrointestinal symptoms were uncom-
mon at presentation, being apparent in 1 patient with
WG. Interestingly, 1 patient was classified as having
juvenile idiopathic arthritis at presentation but was sub-
sequently reclassified as having WG following the devel-
opment of tracheal stenosis and a positive ANCA titre
during disease flares (Patient 5). The diagnosis was con-
firmed by histology in four patients who had a renal
biopsy that demonstrated pauci- immune focal necrotis-
ing glomerulonephritis.
In one patient, the initial presentation was consistent
with polyarteritis nodosa(based on a positive angiogram,
rash, and iritis) but she subsequently developed an MPA
disease pattern, with pauci- immune glomerulonephritis
and MPO-ANCA.
Immunosuppression
All but one patient received cyclophosphamide during
the course of their illness (Table 3). In general, a course
of pulsed cyclophosphamide consisted of fortnightly
doses of IV cyclophospahmide for a total of 3 doses fol-
lowed by three weekly treatment for another 2-4 doses.
A course oral cyclophosphamide (1-2 mg/kg/day) was
for 3- 6 months but also depended on disease activity.
The one patient (with WG) who did not receive cyclo-
phosphamide achieved remission with oral prednisolone
alone. Of those treated with cyclophosphamide, 5
received more than one course. All patients received
oral steroids, and 4 received additional pulsed intrave-
nous methylprednisolone as a part of their induction
therapy, which consisted of 500 mg methylprednisolone
IV daily for 3 days followed be a tapering dose of oral
steroids. Oral steroid exposure was difficult to ascertain
due to the titration of doses during a treatment course.
Steroid treatment consisted of a reducing dose of oral
prednisolone starting at a dose of 1 mg/kg (up to 60
mg). Doses were reduced for the first 6 months down to
10 mg/day. This was tapered over the next 6- 12
months, depending on disease activity.
Biological agents used to achieve remission included
rituximab only (in 2 patients with WG), and alemtuzu-
mab, infliximab, and rituximab (all in 1 patient with
grumbling WG). All biologic agents were given during
Table 1 Patient Demographics
Patient Gender Ethnicity Diagnosis Age at presentation Follow up Time to 1
st relapse(from diagnosis) Total relapses
1 M Caucasian WG 11 years 25 years 56 months 4
2 F Caucasian MPA 14 years 30 years 2 months 4
3 F Caucasian WG 9 years 11 years 91 months 3
4 F Afro-Caribbean WG 9 months 27 years 186 months 6
5 F Caucasian WG 9 years 23 years 11 months 8
6 F Afro-Caribbean WG 12 years 14 years Never reached full remission 2
7 M Caucasian WG 14 years 11 years 16 months 6
8 F Caucasian WG 15 years 12 years 24 months 1
Table 2 Clinical features on presentation
12345678
Constitutional + + +
Fever + +
Arthralgia/arthritis + + + + + +
Renal impairment + + + +
Haematuria + + + + +
Proteinuria + +
Skin lesions + + + + +
Neurological involvement +
Lung involvement + + + +
Haemoptysis + +
Bloody stools +
Sinus involvement + +
Eye involvement + + +
Epistaxis + +
Table 3 Treatment summary
Patient IV
CP
Oral
CP
IV
MP
OSt AZA/
MMF
Cy Biologic
Agents
PEX
1+- - + + - - -
2++- + + + - -
3 + - + + + - Rituximab (x1) 9
cycles
4--- + + + - -
5 - +++ - + + + - -
6 + + + + + + Rituximab (x2)
Infliximab (x1)
Campath (x1)
-
7 + + + + + + Rituximab (x4) -
8- + + + + + - - -
CP: Cyclophosphamide; MP: Methylprednisolone; OSt: Oral steroids; Cy:
Cyclosporin; PEX: Plasma exchange
NB: ‘+’ represents a single course of cyclophosphamide in the Oral
Cyclophosphamide column
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patients were maintained with either azathioprine or
mycophenolate mofetil (MMF).
Outcome
All but 1 patient achieved complete remission (Patient 6),
6 of who remained on long- term maintenance treatment.
All patients experienced disease relapse, with a median of
4 episodes and range from 1 to 8 episodes (Table 1). The
relatively frequent number of relapses may be explained
by the fact that we included even minor relapses. How-
ever, it may also be explained by the possibility that the
described severity of illness in our cohort is due to referral
bias, which may concentrate more severe cases.
The median time to first relapse was 24 months
(range 2 to 186 months). At a median follow up of 18.5
years (range 11-30 years) 1 patient had died (Patient 1),
25 years from initial presentation and following four
relapses, from sudden death ascribed to respiratory
complications of his WG.
Long- term complications of disease and treatment
were significant (Table 4). Steroid induced side effects
were a particular problem in these patients, including
Cushing’s syndrome (n = 2), osteoporosis (n = 2), and
depression (n = 1). 1 patient underwent a hip replace-
ment for avascular necrosis of the femoral head (Patient
5). Infections secondary to immunosuppression were
clinically apparent in 7 of the 8 patients. 2 patients con-
tracted shingles and 2 had candidiasis (oral, vaginal, and
oesophageal). Respiratory tract, urinary tract, and skin
infections were common. None of these episodes, how-
ever, were severe enough to warrant hospital admission
and were treated successfully with a course of antibiotics
as outpatients. Infertility was reported in 4 of the
patients (3 females were amenorrhoeic and one male
was infertile). 1 patient developed breast cancer at the
age of 30 years (Patient 5).
Long- term ENT complicati o n sw e r ec o m m o ni nt h e
WG patients, with 50% suffering from hearing impair-
ment and nasal septal or upper airway deformities.
Other significant treatment- associated complications
included a pneumothorax following emergency bron-
chial stenting for severe sub-glottic stenosis.
Kidney function was generally well preserved, with fol-
low up eGFR (Modified diet in renal disease; MDRD)
between 45 and > 90 ml/min, with a median of 76 ml/
min (excluding patient 7). Patient 7, who presented dia-
lysis- dependent, remained so, until he received a renal
transplant two and a half years after his initial diagnosis.
The renal transplant was subsequently lost 8 months
later due to poor adherence to therapy, and the patient
was then re-established on haemodialysis.
Only 1 patient developed non-glomerular haematuria,
that was secondary to endometriosis of the bladder wall.
Table 4 Disease and treatment related co- morbidities in patient cohort
Patient Infertility Infections Musculo-skeletal and Skin eGFR
(ml/min)
Other
1 + Suppurative skin infections
Shingles
- > 90 Cushing’s syndrome
Steroid- induced depression
Chronic diarrhoea
2 + Glandular fever
Urinary tract infections
Chest infection
Otitis media
Gastroenteritis
Alopecia 45 Nasal septal defect
3 - Shingles
Chest infections
- > 90 -
4 + Oral and vaginal thrush
Fungal skin infection
Urinary tract infection
- 72 Hearing impairment
5 + Shingles
Urinary tract infections
Paronychia
Osteopoerosis
AVN hip
Cyclosporin- induced
hirsuitism
> 90 Cushing’s syndrome
Hearing impairment
Subglottic stenosis
Breast Ca
6 - Oeosphageal Candidiasis
Chest infections
- 60 Pnemothorax post-emergency bronchial
stenting
Nasal septal defect
Bronchial stenosis
Bronchiectasis
Hearing impairment
7 - Recurrent chest and urinary tract
infections
- ESRD -
8 - - Osteopoerosis 76 -
Arulkumaran et al. Pediatric Rheumatology 2011, 9:12
http://www.ped-rheum.com/content/9/1/12
Page 4 of 7No other pre-malignant conditions were found and only
one overt malignancy has been diagnosed in these 8
patients.
In summary, the overall disease and/or treatment
related morbidity was high. Of the 8 patients, 1 patient
died. All patients had relapsing disease; 7 suffered from
infections, 4 were infertile, 2 had skeletal complications
(osteoporosis or AVN of the femoral head); and 1 had
psychiatric complications (depression), and 1 developed
malignancy.
Discussion
We describe the clinical features and long-term out-
comes of 8 children diagnosed with ANCA vasculitis
a n df o l l o w e du pi n t oa d u l t h o o df o ram e d i a no f1 8 . 5
years (mean 19 years; range 11 to 30 years). In addition
to studying our series of patients we reviewed a total of
7 reports that described the clinical course of 86
patients with paediatric onset of WG [3,6,9,10], MPA
[11,12] and ANCA- associated vasculitis and necrotising
glomerulonephritis (GN) [13] (Table 5). Particular
emphasis was placed on treatment and complication
rates. The follow up ranged from 4 months to 11 years.
As the aim of our study was to describe the long- term
follow up of paediatric patients with vasculitis, patients
were only included in our series if they had more than
10 years of follow up.
In the 86 reported patients, the age of disease onset
ranged between 2 weeks and 16 years. However, 2 of
the reports also included follow up of patients who pre-
sented as young adults [3,6]. We limited the upper age
for inclusion in our cohort to 16 years. Only 2 out of
our 8 patients (25%) were male. Similarly, there was a
female predominance among the WG and MPA patients
in the literature, with 68% and 70% of all patients being
female respectively.
The long- term disease and treatment- related mor-
bidity in WG remains a significant concern. Rottem et
al reported a lower rate of treatment- related permanent
morbidity in cyclophosphamide- treated paediatric WG
patients compared to adult patients (22% vs 45%) [3].
Over a median period of 8.3 years, 48% of paediatric
WG patients developed nasal deformities, 17% had hear-
ing loss, 35% had subglottic stenosis, 35% had chronic
kidney disease (9% with end stage renal disease (ESRD)),
48% had chronic sinus disease, 14% had pulmonary
Table 5 Summary of reported case series of paediatric patients with ANCA vasculitis
MPA n M:F Age CKD ESRD Relapse rate Rx Deaths
Bakkalogou
[12]
10 4:6 Median: 12
years
(8- 17)
4
(40%)
4
(40%)
5 episodes Steroids
Oral CP
0
(0%)
Peco- Antic
[11]
7 1:6 Mean: 12
years
(7- 15)
1
(14%)
2
(29%)
Not stated Oral steroids
Oral CP
0
(0%)
Total MPA 17 5:12 7- 17 years 5
(29%)
6
(35%)
Not stated - 0
(0%)
WG n M:F Age CKD ESRD Relapse rate Rx Deaths
Rottem [3] 23 7:16 Mean: 15.4
years
(9- 19)
8
(35%)
2
(9%)
53% of all children and 38% of those with f/u >
5years had > 1 relapse
Oral pred and oral CP 2
(9%)
Stegmayr [6] 10 5:5 11- 30 years 6
(60%)
1
(10%)
Median: 28 months in 80% 9/10 patients received CP
and steroids
0
(0%)
Belostotsky [9] 17 4:13 Mean: 6 years
Median: 6.3
years
(2 weeks - 14
years)
3
(18%)
0
(0%)
Not stated All but one patient
received CP + Pred.
Pred in all patients
2
(12%)
Wong [10] 12 4:8 2 months to
14 years
Not
stated
Not
stated
Not stated Not stated Not
stated
Total WG 62 20:42 2 weeks to
30 years
17
(27%)
3
(5%)
Not stated - -
AAV +
Necrotising
GN
n M:F Age CKD ESRD Relapse rate Rx Deaths
Valentini [13] 7 2:5 13 years
(+/- 0.9)
2
(29%)
1
(14%)
Not stated IV MP + IV CP in all
patients
0
(0%)
Grand total 86 27:
59
2 weeks-
30years
24
(28%)
11
(12%)
-- -
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times more likely to have subglottic stenosis and twice
as likely to have nasal deformities, favouring the use of
more potent immunosuppression.
However, these patients also suffered from significant
treatment related complications. Cystitis was present in
50% and infertility in 28% of patients receiving daily
cyclophosphamide. 43% of patients had an average of 21
serious infections in 200 patient years. The relative risk
of infection as a result of steroid treatment was 2, but
rose to 7 with cyclophosphamide and 12 with both ster-
oids and cyclophosphamide. There were no malignan-
cies reported in this series [3]. Furthermore, Stegmayr
reported regular relapses on stopping cyclophosphamide
[6].
There are two studies describing childhood MPA
[11,12]. Renal involvement appeared to be a predomi-
nant feature of MPA. Rapidly progressive glomerulone-
phritis occurred in 6 out of 10 patients in the series by
Bakkaloglu [12]. Renal disease with biopsy- proven
pauci- immune GN was present in all patients in a ser-
ies by Peco- Antic [11]. The proportion of patients
reaching ESRD was 40% and 29% respectively, with no
deaths. Cyclophosphamide and steroids were used as
induction therapy in both series. Neither series report
long- term treatment related complications.
It is of interest that diagnostic categories may change
with time. One of our cohort was initially diagnosed
with polyarteritis nodosa (positive angiogram, negative
ANCA) but subsequently their disease evolved into
MPA, with evidence of pauci-immune glomerulonephri-
tis and MPO-ANCA positivity.
The morbidity associated with current treatment is
significant. Apart from one of our patients with WG
who achieved remission with prednisolone, all of our
patients received cyclophosphamide, with 5 patients
receiving more than one course. We found a significant
rate of infertility among our patients, with 4 of 8 (50%)
patients affected. A slightly smaller number of patients
(30%) in a review by Rottem et al suffered from inferti-
lity after cyclophosphamide treatment [3]. This is an
obvious concern in the administration of cyclophospha-
mide in young patients. The co- morbidity associated
with steroids is also significant. Rottem found a 2- fold
increase in risk of infection with steroid treatment.
Almost all of our patients had a steroid- related compli-
cation, particularly with long- term therapy.
The use of biologic agents is therefore a therapeutic
strategy that needs exploring. Approximately half of our
patients received biologic agents to control disease activ-
ity. 2 out of these 3 patients have suffered from signifi-
cant infections subsequently. In a recent study by
Eleftheriou et al, 25 paediatric patients with primary sys-
temic vasculitis were treated with biologic agents
including infliximab, rituximab, etanercept, and adalimu-
mab. They found a significant improvement in BVAS
score from 8.5 to 4 over a 32-month period. This was
associated with a significant reduction in oral steroid
requirement from 1.0 to 0.25 mg/kg/day. Notably, the
overall rate of infection was 24%, but was more severe
in those receiving infliximab [14].
In our review, we have included several papers from
different centres with different treatment protocols,
summarised in Table 5. However, it must be emphasised
that our summary of the literature includes papers pub-
lished over several years, with heterogeneity between
patients and treatment protocols. This limitation must
be considered when interpreting the quoted overall
morbidity and mortality rates.
Conclusions
We report significant late morbidity in 8 patients who
presented with ANCA vasculitis in childhood. High
relapse rates and treatment- associated complications
including infection, steroid- related complications and
infertility are of particular concern. Therefore, finding
the most efficacious therapeutic regimen which is asso-
ciated with the least side effects is especially important
in paediatric vasculitis populations as the patients are
likely to live long enough to develop late-therapy asso-
ciated complications. In addition, although not yet
observed in our series, late cardiovascular morbidity
remains a major longer-term potential concern for adult
survivors of paediatric vasculitis, an area of ongoing
active research. Thus our results and those of others
suggest that paediatric survivors of systemic vasculitis
require careful long term follow up into adulthood with
respect to ongoing significant disease activity and treat-
ment related morbidity. Prospective cohort studies
including paediatric patients are crucial to help us deter-
mine the best approach to managing this complex group
of patients.
Abbreviations
AAV: ANCA associated vascuitis; ANCA: Anti- neutrophil cytoplasmic
antibody; BVAS: Birmingham vasculitis activity score; eGFR: Estimated
glomerular filtration rate; ENT: Ear, nose and throat; ESRD: End stage renal
disease; EULAR: European league against rheumatism; GN:
Glomerulonephritis; HSP: Henoch Schonlein purpura; KD: Kawasaki disease;
MMF: Mycophenolate mofetil; MPA: Microscopic polyangiitis; PAN:
Polyarteritis nodosa; RPGN: Rapidly progressive glomerulonephritis; WG:
Wegener’s granulomatosis
Author details
1Renal Section, Division of Medicine, Imperial College London, Hammersmith
Hospital, Ducane Road, London W12 0NN, UK.
2Division of Renal
Immunobiology, Medical School, West Extension, 1st Floor, University of
Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
3Department of
Rheumatology, Institute of Child Health, Great Ormond Street Hospital, 30
Guilford St, London WC1N 1EH, UK.
4Centre for Nephrology, University
College London, Royal Free Hospital, London NW3 2PF, UK.
Arulkumaran et al. Pediatric Rheumatology 2011, 9:12
http://www.ped-rheum.com/content/9/1/12
Page 6 of 7Authors’ contributions
NA was involved in data gathering, writing the manuscript, performing the
literature review, data analysis, and creating the tables. SJ was involved in
data gathering. SS was involved in data gathering. LH is a senior author/
editor and was involved in writing the manuscript. CDP is a senior author/
editor and was involved in writing the manuscript. PB a senior author/editor,
was involved in writing the manuscript, performing the literature review,
and data analysis. ADS is a senior author/editor and was involved in writing
the manuscrip, design of study, and data analysis. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 April 2011 Accepted: 19 June 2011
Published: 19 June 2011
References
1. Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 1997,
337:1512-23.
2. Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al: Juvenile
polyarteritis: Results of a multicenter survey of 110 children. J Pediatr
2004, 145:517-22.
3. Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, et al:
Wegener granulomatosis in children and adolescents: Clinical
presentation and outcome. J Pediatr 1993, 122:26-31.
4. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR: Incidence
of henoch-schonlein purpura, kawasaki disease, and rare vasculitides in
children of different ethnic origins. Lancet 2002, 360:1197-202.
5. Harnden A, Alves B, Sheikh A: Rising incidence of kawasaki disease in
england: Analysis of hospital admission data. BMJ 2002, 324:1424-5.
6. Stegmayr BG, Gothefors L, Malmer B, Muller Wiefel DE, Nilsson K,
Sundelin B: Wegener granulomatosis in children and young adults. A
case study of ten patients. Pediatr Nephrol 2000, 14:208-13.
7. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al: Eular/pres
endorsed consensus criteria for the classification of childhood
vasculitides. Ann Rheum Dis 2006, 65:936-41.
8. Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, et al: Eular points to
consider in the development of classification and diagnostic criteria in
systemic vasculitis. Ann Rheum Dis 2010, 69(10):1744-50, Epub 2010 May 6.
9. Belostotsky VM, Shah V, Dillon MJ: Clinical features in 17 paediatric
patients with wegener granulomatosis. Pediatr Nephrol 2002, 17:754-61.
10. Wong SN, Shah V, Dillon MJ: Antineutrophil cytoplasmic antibodies in
wegener’s granulomatosis. Arch Dis Child 1998, 79:246-50.
11. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, Kostic M, Markovic-
Lipkovski J, Nikolic M, et al: Childhood microscopic polyangiitis associated
with mpo-anca. Pediatr Nephrol 2006, 21:46-53.
12. Bakkaloglu A, Ozen S, Baskin E, Besbas N, Gur-Guven A, Kasapcopur O, et al:
The significance of antineutrophil cytoplasmic antibody in microscopic
polyangitis and classic polyarteritis nodosa. Arch Dis Child 2001, 85:427-30.
13. Valentini RP, Smoyer WE, Sedman AB, Kershaw DB, Gregory MJ,
Bunchman TE: Outcome of antineutrophil cytoplasmic autoantibodies-
positive glomerulonephritis and vasculitis in children: A single-center
experience. J Pediatr 1998, 132:325-8.
14. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al: Biologic
therapy in primary systemic vasculitis of the young. Rheumatology
(Oxford) 2009, 48:978-86.
doi:10.1186/1546-0096-9-12
Cite this article as: Arulkumaran et al.: Long- term outcome of paediatric
patients with ANCA vasculitis. Pediatric Rheumatology 2011 9:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Arulkumaran et al. Pediatric Rheumatology 2011, 9:12
http://www.ped-rheum.com/content/9/1/12
Page 7 of 7